<DOC>
	<DOCNO>NCT01882699</DOCNO>
	<brief_summary>This study build upon previously approve protocol entitle `` A multi-center prospective , blind , randomize crossover study compare Cerêve Sleep System two different temperature primary insomnia patient '' ( CIP-003 ; CER1-01-090 ) . In study , 150 insomnia patient target randomized complete lab assessment sleep use Cerêve Sleep System . In follow-on study , 36 patient complete lab study enrol complete 2 phase home use device . In first phase , durability study , 30 patient target complete additional lab assessment follow 30 day home use device . In second phase , home use pattern study , 24 patient target complete additional 5 month home use use pattern monitor . Hypothesis : EEG sleep latency sleep efficiency follow 30 day home use device 14-16°C similar measure initial acute , 2-night use parent study 14-16°C condition . The device demonstrate benign safety profile 6 month home use .</brief_summary>
	<brief_title>30 Days Home Use Home Use Patterns Over 6 Months</brief_title>
	<detailed_description>Study Design Objectives Clinical Investigation - Assess polysomnographically measure sleep latency sleep efficiency follow 30 day home use device compare measure follow initial lab use CIP-003 protocol . - Determine long-term use pattern Cerêve Sleep System environment intend use . Study Design Overview A multi-center , prospective , non-randomized , two phase study determine durability effect follow 30 day home use ( phase I ) home use pattern additional 5 month home use Cerêve Sleep System ( phase II ) . A total 30 evaluable subject target complete phase I total 24 evaluable subject target complete phase II . It anticipate 36 subject enrol CIP-004 protocol obtain number evaluable subject describe . During home use durability phase home use pattern phase , subject ask use device minimum three night week least 4 hour night seven night week . Subjects complete weekly home use log throughout phase study .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Must complete inlab protocol CIP003 sign inform consent participate followon study . Sleep latency sleep efficiency data available 2 inlab PSG night CIP003 1416° condition , confirm core laboratory . Use medication know affect sleep wake function ( e.g. , hypnotic , benzodiazepine , antidepressant , anxiolytic , antipsychotic , antihistamine , decongestant , beta blocker , corticosteroid ) exclude durability phase , inlab study , protocol ; Beta blocker NOT cross blood brain barrier acceptable . Consumption one alcoholic drink per day , 7 drink per week prior study entry durability phase , inlab study , protocol . Caffeinated beverage &gt; 4/day equivalent 4 cup coffee durability phase , inlab study , protocol . Unable read understand English</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Insomnia</keyword>
</DOC>